Paper38533720
Tumor associated macrophages as key contributors and targets in current and future therapies for melanoma.
Habib S and 15 others. Expert Rev Clin Immunol, 2024. Cited by 22 papers, by iCite.
Cite this record
ConductScience Library. Tumor associated macrophages as key contributors and targets in current and future therapies for melanoma. Papers, record 38533720. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38533720
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Tumor associated macrophages as key contributors and targets in current and future therapies for melanoma.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Melanoma | Major topic |
| Tumor Microenvironment | Major topic |
| Immunotherapy | Major topic |
| Tumor-Associated Macrophages | Major topic |
| Humans | |
| Animals | |
| Molecular Targeted Therapy | |
| Clinical Trials as Topic | |
| Macrophages |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| Wellcome Trust | United Kingdom | PubMed | ||
| MR/V049445/1 | Medical Research Council | United Kingdom | PubMed |
Source PubMed
References157
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33228719 | Tumor-associated macrophage, angiogenesis and lymphangiogenesis markers predict prognosis of non-small cell lung cancer patients. | J Transl Med | 2020 | https://conductscience.org/library/papers/33228719 | PubMed |
| 2 | 35363544 | Human dendritic cells in cancer. | Sci Immunol | 2022 | https://conductscience.org/library/papers/35363544 | PubMed |
| 3 | 33161320 | Breast cancer cells and macrophages in a paracrine-juxtacrine loop. | Biomaterials | 2021 | https://conductscience.org/library/papers/33161320 | PubMed |
| 4 | 28272106 | M1 and M2 macrophages' clinicopathological significance in cutaneous melanoma. | Melanoma Res | 2017 | https://conductscience.org/library/papers/28272106 | PubMed |
| 5 | 26526369 | TGF-β-Induced Transcription Sustains Amoeboid Melanoma Migration and Dissemination. | Curr Biol | 2015 | https://conductscience.org/library/papers/26526369 | PubMed |
| 6 | 26089604 | Understanding the Mysterious M2 Macrophage through Activation Markers and Effector Mechanisms. | Mediators Inflamm | 2015 | https://conductscience.org/library/papers/26089604 | PubMed |
| 7 | 36497391 | Adrenomedullin Secreted by Melanoma Cells Promotes Melanoma Tumor Growth through Angiogenesis and Lymphangiogenesis. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/36497391 | PubMed |
| 8 | 33457097 | Generation of GM-CSF-producing antigen-presenting cells that induce a cytotoxic T cell-mediated antitumor response. | Oncoimmunology | 2020 | https://conductscience.org/library/papers/33457097 | PubMed |
| 9 | 28423340 | Transforming Growth Factor-β Signaling in Regulatory T Cells Controls T Helper-17 Cells and Tissue-Specific Immune Responses. | Immunity | 2017 | https://conductscience.org/library/papers/28423340 | PubMed |
| 10 | 28473638 | Mapping the human DC lineage through the integration of high-dimensional techniques. | Science | 2017 | https://conductscience.org/library/papers/28473638 | PubMed |
| 11 | 28514441 | PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. | Nature | 2017 | https://conductscience.org/library/papers/28514441 | PubMed |
| 12 | 35879449 | The complex role of tumor-infiltrating macrophages. | Nat Immunol | 2022 | https://conductscience.org/library/papers/35879449 | PubMed |
| 13 | 25082815 | CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. | Cancer Res | 2014 | https://conductscience.org/library/papers/25082815 | PubMed |
| 14 | 31166680 | Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. | N Engl J Med | 2019 | https://conductscience.org/library/papers/31166680 | PubMed |
| 15 | 37215144 | The transcriptional control of the VEGFA-VEGFR1 (FLT1) axis in alternatively polarized murine and human macrophages. | Front Immunol | 2023 | https://conductscience.org/library/papers/37215144 | PubMed |
| 16 | 35195495 | BRAF inhibitors and their immunological effects in malignant melanoma. | Expert Rev Clin Immunol | 2022 | https://conductscience.org/library/papers/35195495 | PubMed |
| 17 | 32733446 | Antigen Cross-Presentation by Macrophages. | Front Immunol | 2020 | https://conductscience.org/library/papers/32733446 | PubMed |
| 18 | 26896096 | IFNγ and CCL2 Cooperate to Redirect Tumor-Infiltrating Monocytes to Degrade Fibrosis and Enhance Chemotherapy Efficacy in Pancreatic Carcinoma. | Cancer Discov | 2016 | https://conductscience.org/library/papers/26896096 | PubMed |
| 19 | 36166727 | Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. | J Clin Oncol | 2023 | https://conductscience.org/library/papers/36166727 | PubMed |
| 20 | 35351601 | Macrophage inhibitory cytokine-1 in cancer: Beyond the cellular phenotype. | Cancer Lett | 2022 | https://conductscience.org/library/papers/35351601 | PubMed |
Cited by21
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 22 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42938860 | Reprogramming the Melanoma Tumor Microenvironment: From Cellular Crosstalk to Cellular Immunotherapy. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42938860 | PubMed |
| 42899013 | Innate immune cells in tumor immunity: dual roles, mechanistic insights, and therapeutic opportunities. | Front Immunol | 2026 | https://conductscience.org/library/papers/42899013 | PubMed |
| 42738348 | Rethinking Immunotherapy Resistance in Melanoma: A Narrative Review of Clinical Patterns, Resistance Mechanisms, and Future Strategies. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42738348 | PubMed |
| 42311672 | Melanoma stem cells drive macrophage reprogramming to a hybrid phenotype, modulating melanoma stemness and compromising NK cell-mediated immunity. | Front Immunol | 2026 | https://conductscience.org/library/papers/42311672 | PubMed |
| 42197424 | Listeria monocytogenes-Derived Membrane Vesicles Suppress Melanoma Growth via Macrophage Activation Involving NF-κB Signaling. | Microorganisms | 2026 | https://conductscience.org/library/papers/42197424 | PubMed |
| 42193884 | Beyond Hematology-Current Insights into Chimeric Antigen Receptor (CAR) T-Cell Therapy for Skin and Connective Tissue Disorders. | Cells | 2026 | https://conductscience.org/library/papers/42193884 | PubMed |
| 42166711 | CSF1R-dependent CD169-positive macrophages locally constrain melanoma growth in the skin. | J Exp Med | 2026 | https://conductscience.org/library/papers/42166711 | PubMed |
| 42129932 | The role of galectins in modulating the tumor microenvironment and driving metastasis in skin cancers. | Biol Res | 2026 | https://conductscience.org/library/papers/42129932 | PubMed |
| 41872159 | Melanoma exosomal miR-708-5p promotes macrophage M2 polarization and cancer metastasis. | Cell Death Dis | 2026 | https://conductscience.org/library/papers/41872159 | PubMed |
| 41799379 | Mechanisms and Therapeutic Strategies to Overcome Immune Checkpoint Inhibitor Resistance in Melanoma, Head and Neck, and Triple-Negative Breast Cancers. | J Cell Immunol | 2025 | https://conductscience.org/library/papers/41799379 | PubMed |
| 41419864 | Melanoma treatment in the era of nanotechnology and precision medicine. | J Nanobiotechnology | 2025 | https://conductscience.org/library/papers/41419864 | PubMed |
| 41112239 | Emerging macrophage-based therapies for cancer: a review of preclinical and clinical advances. | Front Immunol | 2025 | https://conductscience.org/library/papers/41112239 | PubMed |
| 40993759 | Engineering macrophages for targeted immunotherapy and drug delivery in melanoma. | J Transl Med | 2025 | https://conductscience.org/library/papers/40993759 | PubMed |
| 40595758 | Unraveling the role of HIF2α in melanoma progression and epithelial-mesenchymal transition. | Sci Rep | 2025 | https://conductscience.org/library/papers/40595758 | PubMed |
| 40573249 | Metabolic Reprogramming in Melanoma: An Epigenetic Point of View. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/40573249 | PubMed |
| 40399946 | Double-sided niche regulation in skin stem cell and cancer: mechanisms and clinical applications. | Mol Cancer | 2025 | https://conductscience.org/library/papers/40399946 | PubMed |
| 40180895 | Exploring the potential of selective FKBP51 inhibitors on melanoma: an investigation of their in vitro and in vivo effects. | Cell Death Discov | 2025 | https://conductscience.org/library/papers/40180895 | PubMed |
| 39769450 | Therapeutic Significance of NLRP3 Inflammasome in Cancer: Friend or Foe? | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39769450 | PubMed |
| 39619202 | The effects of plasma from patients with active thyroid-associated orbitopathy on the survival and inflammation of melanoma-associated fibroblasts. | PeerJ | 2024 | https://conductscience.org/library/papers/39619202 | PubMed |
| 39269597 | Focal adhesion kinase-mediated interaction between tumor and immune cells in the tumor microenvironment: implications for cancer-associated therapies and tumor progression. | Clin Transl Oncol | 2025 | https://conductscience.org/library/papers/39269597 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/38533720
GET https://conductscience.org/api/papers/v1/38533720/references?page=2